Adhesion GPCRs are a large class of surface proteins that recognize chemical and mechanical stimuli in the body. The rapidly expanding body of knowledge on the therapeutic targeting of these receptors ...

Septerna is poised for a pivotal catalyst with upcoming Phase 1 data for SEP-631, targeting mast cell-driven diseases via ...

Researchers at Leipzig University and Shandong University have summarised the therapeutic potential of these receptors in a high-profile study. At present, 17 of the 33 known human adhesion GPCRs are ...

Septerna has reported positive past Phase 1 results for SEP-631, an oral negative allosteric modulator of MRGPRX2, showing robust target engagement, functional pathway blockade, and tolerability ...

Announced positive topline results from TX45 Phase 1b acute hemodynamic clinical trial in patients with Group 2 Pulmonary Hypertension in Heart ...

SEP-631 Demonstrated Robust, Dose-Dependent Inhibition of Icatibant-Induced Skin Wheal Formation, with Complete Inhibition Observed at Doses as ...

MindRank, a clinical-stage artificial intelligence (AI)-empowered drug discovery company, today announced that the first ...

MindRank doses first patient in phase III clinical trial of AI-designed oral GLP-1 receptor agonist, MDR-001: Shanghai Saturday, February 28, 2026, 18:00 Hrs [IST] MindRank, a cli ...

Positive results from the aleniglipron Phase 2 ACCESS programs in December 2025 demonstrated significant weight loss across all doses and up to 15.3% at 36 weeks Topline 44-week data from the ACCESS ...

Creative BioMart, a leading provider of biotechnological services specializing in protein research products and services, has officially launched its detergent micelle platform. This specialized ...

AbCellera Biologics Inc. (NASDAQ: ABCL) Q4 2025 Earnings Call Transcript February 24, 2026 AbCellera Biologics Inc. beats ...

A proof-of-concept study opens up an avenue for treating solid tumours that express low levels of a target antigen.